KR101264441B1 - 올리고펩티드 및 그의 화장용 용도 - Google Patents

올리고펩티드 및 그의 화장용 용도 Download PDF

Info

Publication number
KR101264441B1
KR101264441B1 KR1020077008567A KR20077008567A KR101264441B1 KR 101264441 B1 KR101264441 B1 KR 101264441B1 KR 1020077008567 A KR1020077008567 A KR 1020077008567A KR 20077008567 A KR20077008567 A KR 20077008567A KR 101264441 B1 KR101264441 B1 KR 101264441B1
Authority
KR
South Korea
Prior art keywords
amino acids
seq
unsaturated
rti
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077008567A
Other languages
English (en)
Korean (ko)
Other versions
KR20070065882A (ko
Inventor
필리쁘 무쑤
루이 다누
질 뽈리
쟝-뤽 콩테-오도노
Original Assignee
바스프 뷰티 케어 솔루션즈 프랑스 에스에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바스프 뷰티 케어 솔루션즈 프랑스 에스에이에스 filed Critical 바스프 뷰티 케어 솔루션즈 프랑스 에스에이에스
Publication of KR20070065882A publication Critical patent/KR20070065882A/ko
Application granted granted Critical
Publication of KR101264441B1 publication Critical patent/KR101264441B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
KR1020077008567A 2004-10-18 2005-10-10 올리고펩티드 및 그의 화장용 용도 Expired - Lifetime KR101264441B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292475.3 2004-10-18
EP04292475 2004-10-18

Publications (2)

Publication Number Publication Date
KR20070065882A KR20070065882A (ko) 2007-06-25
KR101264441B1 true KR101264441B1 (ko) 2013-05-14

Family

ID=34931464

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077008567A Expired - Lifetime KR101264441B1 (ko) 2004-10-18 2005-10-10 올리고펩티드 및 그의 화장용 용도

Country Status (6)

Country Link
US (2) US8044028B2 (cg-RX-API-DMAC7.html)
EP (1) EP1802655B1 (cg-RX-API-DMAC7.html)
JP (1) JP5159311B2 (cg-RX-API-DMAC7.html)
KR (1) KR101264441B1 (cg-RX-API-DMAC7.html)
ES (1) ES2426441T3 (cg-RX-API-DMAC7.html)
WO (1) WO2006042661A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170005935A (ko) 2015-07-06 2017-01-17 김철군 동충하초 재배용 배지조성물 및 동충하초 재배방법
KR20190065916A (ko) 2017-12-04 2019-06-12 김철군 동충하초 재배용 배지조성물 및 동충하초의 재배방법

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1802655B1 (en) 2004-10-18 2013-07-24 BASF Beauty Care Solutions S.A.S. Oligopeptides and their use in cosmetics
PL2027152T3 (pl) * 2006-06-13 2012-04-30 Helix Biomedix Inc Fragmenty peptydów do indukowania syntezy białek macierzy zewnątrzkomórkowej
JP5789901B2 (ja) * 2008-05-29 2015-10-07 セラピューティック・ペプタイズ・インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃ Ｐｅｐｔｉｄｅｓ，Ｉｎｃ． 皮膚化粧用組成物におけるオリゴマーバイオサーファクタント
RU2411248C2 (ru) * 2008-11-13 2011-02-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Средство, обладающее антипсихотической активностью
WO2011036048A1 (en) 2009-09-24 2011-03-31 Unilever Nv Disinfecting agent comprising eugenol, terpineol and thymol
WO2011126054A1 (ja) * 2010-04-07 2011-10-13 国立大学法人京都大学 生理活性ペプチド
BR112013013085B1 (pt) 2010-12-07 2018-02-14 Unilever N.V. Composição de cuidados orais, enxaguante bucal, creme dental, dentífrico, método para desinfetar a cavidade oral e uso de uma composição
EA024551B1 (ru) 2011-11-03 2016-09-30 Юнилевер Н.В. Индивидуальная композиция для очищения
WO2013064633A1 (de) * 2011-11-04 2013-05-10 Amp-Therapeutics Gmbh Oncopeltus-peptidderivate als antimikrobielle peptide
FR3012811B1 (fr) * 2013-11-05 2015-12-25 Basf Beauty Care Solutions France Sas Oligopeptides et leurs utilisations
EP3906013A1 (en) 2019-01-02 2021-11-10 The Procter & Gamble Company Skin care compositions containing peptide compound and aphanothece sacrum exopolysaccharide extract
KR102192471B1 (ko) * 2019-10-18 2020-12-17 주식회사 인코스팜 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물
KR102952819B1 (ko) * 2022-11-11 2026-04-16 웰펩 주식회사 피부세포 재생 효과가 우수한 펩타이드 및 이를 포함하는 피부세포 재생 촉진용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU68901A1 (cg-RX-API-DMAC7.html) 1973-11-30 1975-08-20
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
US6713605B1 (en) 1996-04-10 2004-03-30 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
US5830993A (en) 1995-04-10 1998-11-03 Kansas State University Research Foundation Synthetic antimicrobial peptide
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
DE19756377A1 (de) 1997-12-18 1999-06-24 Beiersdorf Ag Verwendung von C¶1¶¶8¶-¶3¶¶8¶-Alkylhydroxystearoylstearat zur Verstärkung der UV-A-Schutzleistung kosmetischer oder dermatologischer Formulierungen
US6231768B1 (en) 1999-01-19 2001-05-15 Nalco Chemical Company Rheology modification of settled solids in mineral processing
FR2788777B1 (fr) 1999-01-22 2003-01-17 Sederma Sa Utilisation cosmetique ou dermopharmaceutique de peptides pour la regulation des dysfonctionnements immunologiques cutanes et dans l'inflammation cutanee induits par le vieillissement ou par les u.v.
CA2368638A1 (en) * 1999-03-26 2000-10-05 Beth Israel Deaconess Medical Center Method for pr-39 peptide regulated stimulation of angiogenesis
CA2388868A1 (en) 1999-10-25 2001-05-03 Beth Israel Deaconess Medical Center Method for pr-39 peptide regulated stimulation of angiogenesis
AU2599001A (en) 1999-12-29 2001-07-09 Beth Israel Deaconess Medical Center Method for pr-39 peptide mediated selective inhibition of ikappabalpha degradation
ATE510852T1 (de) * 2001-10-30 2011-06-15 Dsm Ip Assets Bv Dermopharmazeutisch und kosmetisch wirksame oligopeptide
WO2003042387A1 (fr) * 2001-11-13 2003-05-22 Keio University Nouvelles proteines associees a la keratine des poils
FR2836042B1 (fr) * 2002-02-15 2004-04-02 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques pour diminuer les poches et cernes sous les yeux
CA2501645A1 (en) * 2002-10-10 2004-04-22 Verenium Corporation Proteases, nucleic acids encoding them and methods for making and using them
EP1802655B1 (en) 2004-10-18 2013-07-24 BASF Beauty Care Solutions S.A.S. Oligopeptides and their use in cosmetics

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170005935A (ko) 2015-07-06 2017-01-17 김철군 동충하초 재배용 배지조성물 및 동충하초 재배방법
KR20190065916A (ko) 2017-12-04 2019-06-12 김철군 동충하초 재배용 배지조성물 및 동충하초의 재배방법

Also Published As

Publication number Publication date
US8044028B2 (en) 2011-10-25
JP5159311B2 (ja) 2013-03-06
EP1802655B1 (en) 2013-07-24
JP2008517009A (ja) 2008-05-22
ES2426441T3 (es) 2013-10-23
KR20070065882A (ko) 2007-06-25
US20100137560A1 (en) 2010-06-03
EP1802655A2 (en) 2007-07-04
WO2006042661A3 (en) 2006-07-27
WO2006042661A2 (en) 2006-04-27
US20120172308A1 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
US20120172308A1 (en) Oligopeptides And Their Use In Cosmetics
EP1993508B1 (en) Cosmetic composition comprising a combination of a sugar fatty acid ester with a plant extract of waltheria indica or pisum sativum for skin whitening
US8815814B2 (en) Cosmetic composition containing oligopeptides
US8399415B2 (en) Oligopeptides and cosmetic compositions containing the oligopeptides
US20060110413A1 (en) Novel Molecules dervied from noraporphine
US20100286056A1 (en) Compositions for reducing oxidative stress and uses thereof
EP2410977B1 (en) Cosmetic composition containing calcium citrate and n-acylated aminoalcohol derivative to prevent dry skin and signs of cutaneous ageing
KR101240695B1 (ko) Ｐｔｈ 단편 함유 화장품 제제
JP2003531844A (ja) 植物Ａｒｇａｎｉａｓｐｉｎｏｓａの抽出物を含有する化粧品製剤および／または医薬製剤
EP2196190A1 (en) Skin whitening
FR3012811A1 (fr) Oligopeptides et leurs utilisations

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170426

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20180424

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190423

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PC1801 Expiration of term

St.27 status event code: N-4-6-H10-H14-oth-PC1801

Not in force date: 20251011

Ip right cessation event data comment text: Termination Category : EXPIRATION_OF_DURATION